Go back to News
NEWS
GA_P advises the issuer on the IPO of Labiana Health
24 of May, 2022
Gómez-Acebo & Pombo has advised the issuer in the IPO process of Labiana Health. The company will be the first Spanish veterinary company to enter the market and expects to be listed on BME Growth in mid-June through a capital increase.
Labiana is an animal and human health platform, aimed at raising capital to accelerate its organic and inorganic growth. The company already has a firm commitment from Inveready, which, through a convertible bond, will invest up to 4 million subject to completing the IPO. Labiana’s roadmap envisages issuing new shares equivalent to 30% or 40% of its share capital to raise a significant amount of money that will be used to boost the growth that the group has been experiencing in recent years.
Augusto Piñel, Jacobo Palanca, Emiliano Moreno and Irene Carreño Uría, Mercantil partner and associates, have advised on the transaction.
Labiana is an animal and human health platform, aimed at raising capital to accelerate its organic and inorganic growth. The company already has a firm commitment from Inveready, which, through a convertible bond, will invest up to 4 million subject to completing the IPO. Labiana’s roadmap envisages issuing new shares equivalent to 30% or 40% of its share capital to raise a significant amount of money that will be used to boost the growth that the group has been experiencing in recent years.
Augusto Piñel, Jacobo Palanca, Emiliano Moreno and Irene Carreño Uría, Mercantil partner and associates, have advised on the transaction.
Lawyer mentioned
Augusto Piñel – Partner
Jacobo Palanca – Senior Associate
See all lawyers
See less lawyers
Tipology
Deal
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
10 Oct, 2025 
PUBLICATION
03 Mar, 2026
Legal doctrine of the UPC’s Court of Appeal on the patent invalidity defence: is the way in which the ‘long arm’ is applied compatible with the UPC's own Rules of Procedure?
The Court of Appeal of the Unified Patent Court has ruled that a patent invalidity defence cannot be raised before the Unified Patent Court, with only a counterclaim being possible. This calls into question the way in which the ‘long arm’ is being applied with regard to European patents validated in States that are not party to the Agreement on a Unified Patent Court (UPCA), whether or not they are members of the European Union, since no counterclaim for revocation or plea of invalidity as a defence can be filed or raised with regard to such patents. This raises significant doubts about the compatibility of how the ‘long arm’ is applied in the Unified Patent Court system, given its own Rules of Procedure.
03 Mar, 2026 
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026
PUBLICATION
27 Jan, 2026
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
27 Jan, 2026
PUBLICATION
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026
PUBLICATION
15 Jan, 2026
Financial institutions’ customer services following Act 10/2025
Act 10/2025 reforms the regime governing financial institutions’ customer services and introduces a procedure for the submission, processing and resolution of complaints filed by their customers, including special provisions when such customers are consumers, such as a free helpline and the availability of channels that allow for personalised service to vulnerable consumers or people without access to certain basic financial services that are not defined in the new law.
15 Jan, 2026
PUBLICATION
15 Jan, 2026
Excessive extension of the Bolar clause in the 'pharmaceutical legislative package'
The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.
15 Jan, 2026
PUBLICATION
09 Dec, 2025
Pharma & Healthcare No. 46
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
09 Dec, 2025
PUBLICATION
28 Oct, 2025
Borderline products and the precedence of medicinal product legislation
The application of the rule of precedence requires, firstly, that a given product falls within the legal definition of a medicinal product, whether it is a medicinal product by function or by presentation, and secondly, that there are doubts as to whether it also falls within the legal concept of other types of products (food supplements, cosmetics, etc.).
28 Oct, 2025
PUBLICATION
25 Sep, 2025
Pharma & Healthcare No. 45
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
25 Sep, 2025